Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy

ACS Appl Mater Interfaces. 2022 Sep 28;14(38):42931-42939. doi: 10.1021/acsami.2c11089. Epub 2022 Sep 13.

Abstract

Immune checkpoint blockade (ICB) has been hailed as the hope for conquering cancer as ICB could produce a significant and durable response to tumor cells. However, the high cost and severe side effects of ICB drugs limited their application for further anticancer therapy. Here, we developed a photoactivated immunotherapy nanoplatform (Apt@AuNC). This nanoplatform could target tumor tissues via enhanced penetration retention (EPR) effect and the aptamer (Apt) could be released from Apt@AuNC in tumor sites via illumination. The immune system in the tumor area was then activated after the combination of Apt and PD-1 protein. The heat generated from AuNC was able to continue killing tumor cells. This nanoplatform could not only achieve the precise immunotherapy but also significantly facilitate the anticancer efficacy.

Keywords: aptamer; gold nanocage; immune checkpoint blockade; light targeting; photothermal therapy.

MeSH terms

  • Aptamers, Nucleotide* / pharmacology
  • Aptamers, Nucleotide* / therapeutic use
  • Cell Line, Tumor
  • Dimaprit / analogs & derivatives
  • Gold / pharmacology
  • Gold / therapeutic use
  • Humans
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Nanostructures
  • Neoplasms* / drug therapy
  • Programmed Cell Death 1 Receptor

Substances

  • Aptamers, Nucleotide
  • Immune Checkpoint Inhibitors
  • Programmed Cell Death 1 Receptor
  • APT
  • Gold
  • Dimaprit